Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 61

1.

Role of Nerve Growth Factor (NGF) and miRNAs in Epithelial Ovarian Cancer.

Retamales-Ortega R, Oróstica L, Vera C, Cuevas P, Hernández A, Hurtado I, Vega M, Romero C.

Int J Mol Sci. 2017 Feb 26;18(3). pii: E507. doi: 10.3390/ijms18030507. Review.

2.

Optimal primary management of bulky stage IIIC ovarian, fallopian tube and peritoneal carcinoma: Are the only options complete gross resection at primary debulking surgery or neoadjuvant chemotherapy?

Sioulas VD, Schiavone MB, Kadouri D, Zivanovic O, Roche KL, O'Cearbhaill R, Abu-Rustum NR, Levine DA, Sonoda Y, Gardner GJ, Leitao MM Jr, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):15-20. doi: 10.1016/j.ygyno.2017.02.023. Epub 2017 Feb 21.

PMID:
28238354
3.

A multicenter assessment of the ability of preoperative computed tomography scan and CA-125 to predict gross residual disease at primary debulking for advanced epithelial ovarian cancer.

Suidan RS, Ramirez PT, Sarasohn DM, Teitcher JB, Iyer RB, Zhou Q, Iasonos A, Denesopolis J, Zivanovic O, Long Roche KC, Sonoda Y, Coleman RL, Abu-Rustum NR, Hricak H, Chi DS.

Gynecol Oncol. 2017 Apr;145(1):27-31. doi: 10.1016/j.ygyno.2017.02.020. Epub 2017 Feb 14.

PMID:
28209497
6.

In Pursuit of Optimal Cytoreduction in Ovarian Cancer Patients: The Role of Surgery and Surgeon.

Shashikant L, Kesterson Joshua P.

J Obstet Gynaecol India. 2009 May-Jun;59(3):209-216.

7.

Comparison of survival outcomes after recurrence detected by cancer antigen 125 elevation versus imaging study in epithelial ovarian cancer.

Paik ES, Kim TJ, Lee YY, Choi CH, Lee JW, Kim BG, Bae DS.

J Gynecol Oncol. 2016 Sep;27(5):e46. doi: 10.3802/jgo.2016.27.e46. Epub 2016 May 9.

9.

Patients with Advanced Ovarian Cancer Administered Oral Etoposide following Taxane as Maintenance Chemotherapy.

Nagano H, Tachibana Y, Kawakami M, Ueno M, Morita Y, Muraoka M, Takagi K.

Case Rep Oncol. 2016 Mar 23;9(1):195-204. doi: 10.1159/000445287. eCollection 2016 Jan-Apr.

10.

Advanced Ovarian Cancer: Primary or Interval Debulking? Five Categories of Patients in View of the Results of Randomized Trials and Tumor Biology: Primary Debulking Surgery and Interval Debulking Surgery for Advanced Ovarian Cancer.

Makar AP, Tropé CG, Tummers P, Denys H, Vandecasteele K.

Oncologist. 2016 Jun;21(6):745-54. doi: 10.1634/theoncologist.2015-0239. Epub 2016 Mar 23. Review.

PMID:
27009938
11.

Results of optimal debulking surgery with bowel resection in patients with advanced ovarian cancer.

Derlatka P, Sienko J, Grabowska-Derlatka L, Palczewski P, Danska-Bidzinska A, Bidzinski M, Czajkowski K.

World J Surg Oncol. 2016 Feb 29;14:58. doi: 10.1186/s12957-016-0800-1.

12.

Selecting the best strategy of treatment in newly diagnosed advanced-stage ovarian cancer patients.

Minig L, Zorrero C, Iserte PP, Poveda A.

World J Methodol. 2015 Dec 26;5(4):196-202. doi: 10.5662/wjm.v5.i4.196. eCollection 2015 Dec 26. Review.

13.

Integrated care in ovarian cancer “IgV Ovar”: results of a German pilot for higher quality in treatment of ovarian cancer.

Keyver-Paik MD, Abramian A, Domröse C, Döser A, Höller T, Friedrich M, Meier W, Menn K, Kuhn W.

J Cancer Res Clin Oncol. 2016 Feb;142(2):481-7.

14.

Radical surgery versus standard surgery for primary cytoreduction of bulky stage IIIC and IV ovarian cancer: an observational study.

Ren Y, Jiang R, Yin S, You C, Liu D, Cheng X, Tang J, Zang R.

BMC Cancer. 2015 Aug 13;15:583. doi: 10.1186/s12885-015-1525-1.

15.

Role of aggressive surgical cytoreduction in advanced ovarian cancer.

Chang SJ, Bristow RE, Chi DS, Cliby WA.

J Gynecol Oncol. 2015 Oct;26(4):336-42. doi: 10.3802/jgo.2015.26.4.336. Epub 2015 Jul 17. Review.

16.

Clinical significance of systematic retroperitoneal lymphadenectomy during interval debulking surgery in advanced ovarian cancer patients.

Iwase H, Takada T, Iitsuka C, Nomura H, Abe A, Taniguchi T, Takizawa K.

J Gynecol Oncol. 2015 Oct;26(4):303-10. doi: 10.3802/jgo.2015.26.4.303. Epub 2015 Jul 17.

17.

Pancreaticoduodenectomy in optimal primary cytoreduction of epithelial ovarian cancer: A case report and review of the literature.

Beissel JM, Kendrick ML, Podratz KC, Bakkum-Gamez JN.

Gynecol Oncol Rep. 2014 Sep 28;10:25-7. doi: 10.1016/j.gore.2014.09.001. eCollection 2014 Dec.

18.

Risk stratification and outcomes of women undergoing surgery for ovarian cancer.

Patankar S, Burke WM, Hou JY, Tergas AI, Huang Y, Ananth CV, Neugut AI, Hershman DL, Wright JD.

Gynecol Oncol. 2015 Jul;138(1):62-9. doi: 10.1016/j.ygyno.2015.04.037. Epub 2015 May 11.

19.

A framework for a personalized surgical approach to ovarian cancer.

Nick AM, Coleman RL, Ramirez PT, Sood AK.

Nat Rev Clin Oncol. 2015 Apr;12(4):239-45. doi: 10.1038/nrclinonc.2015.26. Epub 2015 Feb 24. Review.

20.

Comparative effectiveness research in gynecologic oncology.

Patankar S, Tergas AI, Wright JD.

Cancer Treat Res. 2015;164:237-59. doi: 10.1007/978-3-319-12553-4_13.

Supplemental Content

Support Center